Aki Kido, Ikuko Ohta, Yuki Himoto, Shinya Fujii, Kyo Noguchi, Yuji Nakamoto, Toshihide Ogawa. Uterine peristalsis of adenomyosis patients on cine magnetic resonance imaging. International Journal of Gynecology & Obstetrics. 2025
Yuki Himoto, Koji Fujimoto, Yoshitsugu Chigusa, Atsushi Yoshida, Sachiko Minamiguchi, Aki Kido, Yuji Nakamoto. Toward Clinical Implementation of Magnetic Resonance Imaging for Placental Function. Magnetic Resonance in Medical Sciences. 2025
Mitsuhiro Kirita, Yuki Himoto, Yasuhisa Kurata, Aki Kido, Koji Fujimoto, Hiroyasu Abe, Yuka Matsumoto, Kumi Harada, Satoshi Morita, Ken Yamaguchi, et al. Feasibility/clinical utility of half-Fourier single-shot turbo spin echo imaging combined with deep learning reconstruction in gynecologic magnetic resonance imaging. Abdominal radiology (New York). 2024
Yuki Himoto, Aki Kido, Koji Yamanoi, Yasuhisa Kurata, Satoshi Morita, Nao Kikkawa, Hideyuki Fukui, Ayumi Ohya, Yuko Iraha, Takahiro Tsuboyama, et al. Limited diagnostic performance of imaging evaluation for staging in gastric-type endocervical adenocarcinoma: a multi-center study. Japanese Journal of Radiology. 2024
Masako Kataoka, Yuki Himoto. Editorial for “Deep Learning Radiomic Analysis of MRI Combined with Clinical Characteristics Diagnoses Placenta Accreta Spectrum and its Subtypes”. Journal of Magnetic Resonance Imaging. 2024
Kosuke Kawaguchi, Masahiro Takada, Takeshi Kotake, Michio Yoshimura, Ryuji Uozumi, Masako Kataoka, Takahiko Koyama, Reitaro Tokumasu, Maya Honda, Rikiya Yamashita, et al. Alteration of the tumor immune microenvironment signatures by nivolumab combined with radiation therapy for patients with metastatic breast cancer (Translational Research of the KBCRN-B-002 trial). CANCER RESEARCH. 2020. 80. 4
Masahiro Takada, Michio Yoshimura, Kosuke Kawaguchi, Takeshi Kotake, Ryuji Uozumi, Masako Kataoka, Takahiko Koyama, Hironori Kato, Hiroshi Yoshibayashi, Hirofumi Suwa, et al. A multicenter phase Ib/II study for evaluating safety and efficacy of Nivolumab in combination with radiation therapy in patients with HER2-negative metastatic breast cancer (KBCRN-B-002 trial). CANCER RESEARCH. 2020. 80. 4